

RESEARCH ARTICLE

Open Access

Dynamic contrast-enhanced magnetic resonance imaging of metacarpophalangeal joints reflects histological signs of synovitis in rheumatoid arthritis

Stefan Vordenbäumen^{1*†}, Christoph Schleich^{2†}, Tim Lögters³, Philipp Sewerin¹, Ellen Bleck¹, Thomas Pauly⁴, Anja Müller-Lutz², Gerald Antoch², Matthias Schneider¹, Falk Miese² and Benedikt Ostendorf¹

Abstract

Introduction: Synovial inflammation and joint destruction in rheumatoid arthritis (RA) may progress despite clinical remission. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is increasingly used to detect synovial inflammation in RA. Although small joints such as metacarpophalangeal (MCP) joints are mainly affected by RA, MRI findings have never been directly compared to histological synovitis in MCP synovial tissue. The objective of the current study was therefore to analyse if DCE-MRI relates to histological signs of synovitis small RA joints.

Methods: In 9 RA patients, DCE-MRI (3 Tesla, dynamic 2D T1 weighted turbo-flash sequence) of the hand was performed prior to arthroscopically-guided synovial biopsies from the second MCP of the imaged hand. Maximum enhancement (ME), rate of early enhancement, and maximum rate of enhancement were assessed in the MCP. Synovial biopsies were stained for determination of sublining CD68 and the Synovitis Score. Correlations between MRI and histological data were calculated according to Spearman.

Results: ME of the MCP significantly correlated to sublining CD68 staining ($r = 0.750$, $P = 0.02$), the Synovitis Score ($r = 0.743$, $P = 0.02$), and the subscores for lining layer hypertrophy ($r = 0.789$, $P = 0.01$) and cellular density ($r = 0.842$; $P = 0.004$).

Conclusions: Perfusion imaging of synovial tissue in RA finger joints employing DCE-MRI reflects histological synovial inflammation. According to our study, ME is the most closely associated parameter amongst the measures considered.

Introduction

Rheumatoid arthritis (RA) is a debilitating disease characterized by chronic inflammation and proliferation of synovial tissue with subsequent destruction of cartilage and bone [1]. The target of modern therapeutic strategies consists of complete remission, which is commonly identified based on clinical grounds in conjunction with inflammatory markers such as C-reactive protein [2]. However, joint destruction may progress in patients thus considered to be in remission [3,4]. Hence, additional

tools are needed to directly assess synovitis and cartilage destruction. Magnetic resonance imaging (MRI) is increasingly used for this purpose [5]. In particular, synovitis in MRI has been shown to relate to the histological degree of synovial inflammation in human RA [6,7] and arthritis models [8,9]. Generally, most correlative studies on MRI and synovial histology in RA were performed on large joints, especially knee joints [6,7], due to more easily accessible synovial tissue [10,11]. These findings are commonly extrapolated when MRI findings of small joints are assessed that are predominantly involved in RA, particularly in early disease states [12]. Data validating MRI findings by synovial histology of metacarpophalangeal (MCP) joints are so far scarce: gadolinium

* Correspondence: stefan.vordenbaeumen@med.uni-duesseldorf.de

†Equal contributors

¹Department of Rheumatology, Heinrich-Heine-University, Moorenstraße 5, Düsseldorf 40225, Germany

Full list of author information is available at the end of the article

enhancement in synovial tissue correlated with macroscopic findings of hyperemia and vascularity, but synovial biopsies were not systematically assessed [13]. Data on dynamic MRI of MCP joints and corresponding histological findings are lacking. In the current study, we performed contrast-enhanced dynamic MRI of the hand with determination of perfusion parameters of synovial tissue of the MCP2 joint prior to arthroscopically guided synovial sampling of the same joint with histological analysis of synovial inflammation, with the aim to correlate dynamic MRI to histological synovitis.

Methods

Patients and synovial sampling

Nine patients with RA based on 2010 American College of Rheumatology/European League Against Rheumatism criteria with a 28-joint disease activity score (DAS28) >3.2, who required initiation of disease-modifying antirheumatic drug therapy (three patients, methotrexate) or a switch of medication (patients with methotrexate additionally received adalimumab (four patients), tocilizumab (one patient), or rituximab (one patient)) and gave their full informed written consent, were recruited into the study. After clinical examination (including DAS28, patient-reported ratings on 10-point scales for pain of the dominant MCP2 joint and global well-being, physician-rated 68-tender and swollen joint count), all patients received MRI of the more severely affected hand up to 1 week prior to arthroscopy-guided synovial sampling as described previously [10]. A total of six synovial biopsies were obtained from each patient under visual control from macroscopically inflamed areas and were snap frozen in Tissue-Tek (Sakura Finetek Germany, Staufen, Germany). The study was conducted according to the principles expressed in the Declaration of Helsinki and was approved by the ethics committee of the Medical Faculty of Heinrich-Heine-University (study number 3390).

Histological assessment of synovitis

The work-up and scoring of tissue sections was carried out in a blinded fashion as described previously [10]. Briefly, 3 to 5 μm sections were prepared from snap-frozen synovial tissue, hematoxylin and eosin stained (Merck, Darmstadt, Germany) and evaluated prior to immunohistochemical staining of parallel sections of a suitable biopsy including a lining layer with a monoclonal mouse anti-CD68 antibody (Dako, Glostrup, Denmark). Hematoxylin and eosin -stained sections were used for determination of the synovitis score according to Krenn and colleagues [14], which is a semiquantitative four-point sum scale considering lining layer hypertrophy, inflammatory infiltrate, and density of resident cells. For scoring of sublining CD68 staining, images were photographed at 100 \times magnification (Axioskop 2 plus; Carl Zeiss, Jena, Germany;

and Nikon DS Vi 1; Nikon, Düsseldorf, Germany) and stored in TIF format (resolution of 1,600 \times 1,200). ImageJ software [15] was used to select the sublining layer, and the image was thresholded to highlight the stained areas but not the respective isotype controls. The stained area was calculated as a fraction of the selected region.

Magnetic resonance imaging

MRI was performed on a 3 T MRI system (Magnetom Trio; Siemens Healthcare, Erlangen, Germany). Perfusion imaging (dynamic contrast-enhanced MRI) was acquired with a dynamic two-dimensional T1-weighted turbo-flash sequence. Twenty seconds after the beginning of the sequence, the contrast agent Magnevist[®] (Gd-DTPA, Bayer Healthcare, Leverkusen, Germany) was injected at a dosage of 0.4 ml/kg body weight. The acquisition parameters of the dynamic contrast-enhanced MRI sequence were: repetition time = 333 milliseconds, echo time = 1.46 milliseconds, acquisition time per scan acquisition time = 1.7 seconds, flip angle = 8 $^\circ$, field of view = 120 \times 120 mm, 200 dynamical images and five acquired slices with a slice thickness of 4 mm.

Perfusion analysis in MCP joint synovial tissue was assessed using semiquantitative analysis parameters calculated with T-One weighted Perfusion imaging Parameter Calculation Toolkit software (TOPPCAT, Daniel P. Barboriak, Duke University School of Medicine, Durham, North Carolina, USA). In definite region of interest TOPPCAT analyses, the mean signal intensity ($S(t)$) over time was employed to calculate the maximum level of synovial enhancement (ME), the maximum rate of enhancement (MV) per second, and the rate of early enhancement (REE) 17 seconds after onset of synovial enhancement using the formulas:

$$\text{ME} = \text{maximum}(S(t)) - \text{minimum}(S(t))$$

$$\text{MV} = \text{maximum}(S(i+1) - S(i-1)) / (t(i+1) - t(i-1))$$

$$\text{REE} = (S_2 - S_i) / (S_i \times 17 \text{ seconds}) \times 100\%$$

where S_i is the signal intensity at time point t_i , S_1 is the signal intensity at onset of synovial enhancement, and S_2 is the signal intensity 17 seconds after onset of synovial enhancement. In our study, REE was calculated 17 seconds after onset of synovial enhancement because we acquired a dynamic image every 1.7 seconds. Thus, we used the first 10 breakpoints for REE calculation. In all patients, the region of interest was defined as the anatomical area corresponding to the synovial membrane based on contrast-enhanced T1 images.

Statistical analysis

Correlations between MRI parameters (ME, REE, MV) and parameters of histological synovitis (Synovitis Score, sublining CD68 staining) or clinical data were calculated

Table 1 Correlation between dynamic MRI and histological signs of synovitis in MCP2 joints according to Spearman

	ME	REE	MV
Synovitis Score ^a	0.743 (P = 0.02)	0.228 (P = 0.56)	0.270 (P = 0.48)
Lining layer hypertrophy	0.789 (P = 0.01)	0.177 (P = 0.65)	0.346 (P = 0.36)
Inflammatory infiltrate	0.249 (P = 0.52)	0.053 (P = 0.89)	-0.107 (P = 0.78)
Cellular density	0.842 (P = 0.004)	0.408 (P = 0.28)	0.461 (P = 0.21)
Sublining CD68	0.750 (P = 0.02)	0.450 (P = 0.22)	0.567 (P = 0.11)

Significant results in bold. MCP, metacarpophalangeal; ME, maximum synovial enhancement; MRI, magnetic resonance imaging; MV maximum enhancement velocity; REE, rate of early enhancement. ^aSynovitis Score according to Krenn and colleagues [14].

according to Spearman. $P < 0.05$ was considered significant. SPSS 22 (IBM, Armonk, NY, USA) was used for analyses.

Results

Nine patients (seven female, two male, age 57.5 ± 14.3 years) were recruited, all of whom adhered to the study protocol. Mean DAS28 at inclusion was 5.4 (range 3.5 to 7.4). In the follow-up, there were no severe adverse events within 6 months such as any permanent tissue damage, damage to nerves or vessels, infections, thrombosis, or embolisms following arthroscopy of the MCP2 joint. The median histologic Synovitis Score was 6 (range 1 to 9), corresponding to a high-grade synovitis (score >4 [14]) in seven of nine patients.

Next, we compared dynamic MRI findings with clinical characteristics of the patients. Patient-rated pain of the MCP2 joint on a 10-point scale correlated very strongly with ME ($r = 0.848$, $P < 0.005$), and to a somewhat lesser extent with REE ($r = 0.681$, $P = 0.04$) and MV ($r = 0.695$, $P = 0.04$). No correlations were noted

between the MRI parameters of the MCP2 and the global patient assessment on a 10-point scale, total tender or swollen joint count. Furthermore, a nonsignificant correlation between the DAS28 and ME ($r = 0.661$, $P = 0.053$) was noted.

Finally, dynamic MRI parameters were compared with histological signs of synovitis by correlation analysis. As can be seen in Table 1 and is exemplified in Figure 1, strong correlations between ME and several histological measures of synovitis were present. No such correlations were found for either REE or MV.

Discussion

Recent developments in MRI technology are increasingly used to visualize all anatomical components of joints in RA down to a molecular level and permit functional imaging; for example, the assessment of synovial perfusion [16,17]. Findings such as bone marrow edema have prognostic value for future erosive disease [18]. Many of these findings have been validated on histological




Figure 1 Contrast-enhanced T1-weighted magnetic resonance imaging of metacarpophalangeal (MCP) joints 2 and 3 and maximum synovial enhancement of MCP 2. Illustration of contrast-enhanced T1-weighted magnetic resonance imaging of metacarpophalangeal joint 2 and joint 3 (CE-MRI T1), fusion image of CE-MRI T1 and maximum synovial enhancement of MCP 2 measured by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI), and histological samples from the imaged joint stained with hematoxylin and eosin (HE) or immunohistochemical staining for macrophages (CD68). Patient with (A) a high degree of synovitis and (B) a low degree of synovitis. Red corresponds to a high maximum enhancement.

specimens, such as bone marrow edema and erosions [19,20], or synovial contrast enhancement and synovitis [6,7,9]. These studies have been performed in animal models or knee joints. However, RA has a predilection for small joints such as the MCP joints. Owing to a lack of other data, the validity of MRI findings of synovitis was hitherto extrapolated from large to small joints based on the abovementioned pioneering works. In the present study, we demonstrate that synovitis of MCP joints measured by ME on dynamic MRI strongly correlates to histological inflammation within the same joint. Besides conventional histological criteria, this finding extends to sublining CD68 staining, which is considered one of the best histological markers for disease activity in RA by many experts [21]. These data underscore the validity of dynamic contrast-enhanced MRI for the assessment of the degree of synovitis in small joints.

There are some limitations to this study. The small sample size is due to the invasiveness of the arthroscopic procedure and the resultant effort to keep the number of patients as small as possible with respect to the aim of the study. In spite of this, significant and consistent results were obtained. Moreover, additional synovial parameters could have been assessed such as markers of diverse cell populations and adhesion molecules. However, biopsies of MCP joints did not yield material in sufficient quality for multiple analyses in all cases. Of note, we applied a comparatively high dose of the contrast agent Magnevist® according to a standardized RA study protocol in our facility, which theoretically permits additional analyses such as delayed gadolinium-enhanced MRI [17].

Conclusion

ME measured by dynamic MRI reflects histologic synovitis and may replace invasive sampling of synovial tissue in larger studies for the assessment of the degree of synovitis of small joints such as MCP. Our findings strongly support the use of dynamic MRI to assess synovitis in small joints of RA patients in a clinical setting.

Abbreviations

DAS28: 28-joint disease activity score; MCP: metacarpophalangeal; ME: maximum synovial enhancement; MRI: magnetic resonance imaging; MV: maximum rate of enhancement; RA: rheumatoid arthritis; REE: rate of early enhancement; TOPPCAT: T-One weighted perfusion imaging parameter Calculation toolkit.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

SV participated in the conception of the study, carried out arthroscopies and synovial biopsies, read synovial histologies, interpreted data, followed-up patients, and drafted the manuscript. CS read MRI sequences and interpreted data. TL participated in the conception of the study, and carried out arthroscopies and synovial biopsies. PS participated in the conception of the study and patient follow-up. EB prepared and stained synovial tissue, and participated in data interpretation. TP carried out synovial biopsies, AM-L established and visualized dynamic MRI sequences. GA participated in the

conception of the study. MS participated in the conception of the study and data interpretation. FM participated in the conception of the study, read MRI sequences and interpreted data. BO participated in the conception of the study, interpreted data, and drafted the manuscript. All authors read, revised and approved the final manuscript.

Acknowledgements

The authors gratefully acknowledge financial support of this study by grants from Forschungskommission of the Medical Faculty of Heinrich-Heine-University, Düsseldorf, Germany and the Hiller-Stiftung, Erkrath, Germany. The study was partially supported by a grant from Deutsche Forschungsgemeinschaft (MI 1575/1-1).

Author details

¹Department of Rheumatology, Heinrich-Heine-University, Moorenstraße 5, Düsseldorf 40225, Germany. ²Department of Diagnostic and Interventional Radiology, University Düsseldorf, Medical Faculty, Moorenstraße 5, Düsseldorf 40225, Germany. ³Department of Trauma and Hand Surgery, Heinrich-Heine-University, Moorenstraße 5, Düsseldorf 40225, Germany. ⁴Department of Orthopaedics, River Rhein Center for Rheumatology at St. Elisabeth Hospital, Hauptstraße 74, Meerbusch-Lank 40668, Germany.

Received: 17 June 2014 Accepted: 4 September 2014

Published online: 01 October 2014

References

- McInnes IB, Schett G: **The pathogenesis of rheumatoid arthritis.** *N Engl J Med* 2011, **365**:2205–2219.
- Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LHD, Funovits J, Aletaha D, Allaart CF, Bathon J, Bombardieri S, Brooks P, Brown A, Matucci-Cerinic M, Choi H, Combe B, de Wit M, Dougados M, Emery P, Furst D, Gomez-Reino J, Hawker G, Keystone E, Khanna D, Kirwan J, Kvien TK, Landewe R, Listing J, Michaud K, Martin-Mola E, Montie P, et al: **American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials.** *Ann Rheum Dis* 2011, **70**:404–413.
- Brown AK, Quinn MA, Karim Z, Conaghan PG, Peterfy CG, Hensor E, Wakefield RJ, O'Connor PJ, Emery P: **Presence of significant synovitis in rheumatoid arthritis patients with disease-modifying antirheumatic drug-induced clinical remission: evidence from an imaging study may explain structural progression.** *Arthritis Rheum* 2006, **54**:3761–3773.
- Brown AK, Conaghan PG, Karim Z, Quinn MA, Ikeda K, Peterfy CG, Hensor E, Wakefield RJ, O'Connor PJ, Emery P: **An explanation for the apparent dissociation between clinical remission and continued structural deterioration in rheumatoid arthritis.** *Arthritis Rheum* 2008, **58**:2958–2967.
- Haavardsholm EA, Lie E, Lillegraven S: **Should modern imaging be part of remission criteria in rheumatoid arthritis?** *Best Pract Res Clin Rheumatol* 2012, **26**:767–785.
- Ostergaard M, Stoltenberg M, Løvgreen-Nielsen P, Volck B, Sonne-Holm S, Lorenzen I: **Quantification of synovitis by MRI: correlation between dynamic and static gadolinium-enhanced magnetic resonance imaging and microscopic and macroscopic signs of synovial inflammation.** *Magn Reson Imaging* 1998, **16**:743–754.
- Ostergaard M, Stoltenberg M, Løvgreen-Nielsen P, Volck B, Jensen CH, Lorenzen I: **Magnetic resonance imaging-determined synovial membrane and joint effusion volumes in rheumatoid arthritis and osteoarthritis: comparison with the macroscopic and microscopic appearance of the synovium.** *Arthritis Rheum* 1997, **40**:1856–1867.
- Tamai K, Yamato M, Yamaguchi T, Ohno W: **Dynamic magnetic resonance imaging for the evaluation of synovitis in patients with rheumatoid arthritis.** *Arthritis Rheum* 1994, **37**:1151–1157.
- Jacobson PB, Morgan SJ, Wilcox DM, Nguyen P, Ratajczak CA, Carlson RP, Harris RR, Nuss M: **A new spin on an old model: in vivo evaluation of disease progression by magnetic resonance imaging with respect to standard inflammatory parameters and histopathology in the adjuvant arthritic rat.** *Arthritis Rheum* 1999, **42**:2060–2073.
- Vordenbäumen S, Sewerin P, Lögters T, Miese F, Schleich C, Bleck E, Philippski P, Schädel-Höpfner M, Pauly T, Schneider M, Ostendorf B: **Inflammation and vascularisation markers of arthroscopically-guided finger joint synovial biopsies reflect global disease activity in rheumatoid arthritis.** *Clin Exp Rheumatol* 2014, **32**:117–120.

11. Vordenbäumen S, Joosten LA, Friemann J, Schneider M, Ostendorf B: **Utility of synovial biopsy.** *Arthritis Res Ther* 2009, **11**:256.
12. Mjaavatten MD, Haugen AJ, Helgetveit K, Nygaard H, Sidenvall G, Uhlig T, Kvien TK: **Pattern of joint involvement and other disease characteristics in 634 patients with arthritis of less than 16 weeks' duration.** *J Rheumatol* 2009, **36**:1401–1406.
13. Ostendorf B, Peters R, Dann P, Becker A, Scherer A, Wedekind F, Friemann J, Schulitz KP, Mödder U, Schneider M: **Magnetic resonance imaging and miniarthroscopy of metacarpophalangeal joints: sensitive detection of morphologic changes in rheumatoid arthritis.** *Arthritis Rheum* 2001, **44**:2492–2502.
14. Krenn V, Morawietz L, Burmester G-R, Kinne RW, Mueller-Ladner U, Muller B, Haupl T: **Synovitis Score: discrimination between chronic low-grade and high-grade synovitis.** *Histopathology* 2006, **49**:358–364.
15. **Image J.** [<http://imagej.nih.gov/ij/>]
16. McQueen FM: **Imaging in early rheumatoid arthritis.** *Best Pract Res Clin Rheumatol* 2013, **27**:499–522.
17. Miese F, Buchbender C, Scherer A, Wittsack H-J, Specker C, Schneider M, Antoch G, Ostendorf B: **Molecular imaging of cartilage damage of finger joints in early rheumatoid arthritis with delayed gadolinium-enhanced magnetic resonance imaging.** *Arthritis Rheum* 2012, **64**:394–399.
18. Bøyesen P, Haavardsholm EA, Ostergaard M, van der Heijde D, Sesseng S, Kvien TK: **MRI in early rheumatoid arthritis: synovitis and bone marrow oedema are independent predictors of subsequent radiographic progression.** *Ann Rheum Dis* 2011, **70**:428–433.
19. Albrecht A, Finzel S, Englbrecht M, Rech J, Hueber A, Schlechtweg P, Uder M, Schett G: **The structural basis of MRI bone erosions: an assessment by microCT.** *Ann Rheum Dis* 2013, **72**:1351–1357.
20. Jimenez-Boj E, Nöbauer-Huhmann I, Hanslik-Schnabel B, Dorotka R, Wanivenhaus A-H, Kainberger F, Trattnig S, Axmann R, Tsuji W, Hermann S, Smolen J, Schett G: **Bone erosions and bone marrow edema as defined by magnetic resonance imaging reflect true bone marrow inflammation in rheumatoid arthritis.** *Arthritis Rheum* 2007, **56**:1118–1124.
21. Bresnihan B, Pontifex E, Thurlings RM, Vinkenoog M, El-Gabalawy H, Fearon U, Fitzgerald O, Gerlag DM, Rooney T, van de SANDE MG, Veale D, Vos K, Tak P-P: **Synovial tissue sublining CD68 expression is a biomarker of therapeutic response in rheumatoid arthritis clinical trials: consistency across centers.** *J Rheumatol* 2009, **36**:1800–1802.

doi:10.1186/s13075-014-0452-x

Cite this article as: Vordenbäumen *et al.*: Dynamic contrast-enhanced magnetic resonance imaging of metacarpophalangeal joints reflects histological signs of synovitis in rheumatoid arthritis. *Arthritis Research & Therapy* 2014 **16**:452.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

